ESC 2024: Obicetrapib – a promising breakthrough for dyslipidemia treatment

At ESC 2024, Dr. Erin Michos discussed the success of obicetrapib trials, showing its ability to reduce LDL. Completion of Phase III TANDEM trial enrollment brings NewAmsterdam closer to launching obicetrapib for HeFH/ASCVD. If successful, it could offer a new treatment for high cholesterol, addressing the unmet need for Lp(a) reduction.


Related News

ESC 2024: Obicetrapib – a promising breakthrough for dyslipidemia treatment

At ESC 2024, Dr. Erin Michos discussed the success of obicetrapib trials, showing its ability to reduce LDL. Completion of Phase III TANDEM trial enrollment brings NewAmsterdam closer to launching obicetrapib for HeFH/ASCVD. If successful, it could offer a new treatment for high cholesterol, addressing the unmet need for Lp(a) reduction.

© Copyright 2024. All Rights Reserved by MedPath